Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Age as a determinant of systemic therapy initiation in advanced colorectal cancer: Experience from an urban safety-net hospital.

Daniel Moncada, Yazmin Reategui-Almonacid, Nkengeh Tazinkeng et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13763

e13763 Background: Access is often cited as the primary hurdle in safety-net oncology, yet geriatric factors may drive tre...

Validating a single-item screener for low digital health literacy among surgical oncology patients.

Thomas S. Gunning, Heather Derry-Vick, Lora J. Kasselman et al. Jun 01, 2026 pp. 1634-1634 10.1200/jco.2026.44.16_suppl.1634

1634 Background: Digital health literacy (DHL; the ability to find and understand health information using electronic medi...

Combining HC-7366 with belzutifan in patients with renal cell carcinoma to alter tumor and microenvironment: Pharmacokinetic and pharmacodynamic (PK/PD) analysis of a phase 1b study.

Benjamin Garmezy, Hamid Emamekhoo, Edward Paul Gelmann et al. Jun 01, 2026 pp. 4535-4535 10.1200/jco.2026.44.16_suppl.4535

4535 Background: Clear cell renal cell carcinoma (ccRCC), characterized by loss of von Hippel-Lindau (VHL) tumor suppresso...

Timing of statin initiation for primary atherosclerotic cardiovascular disease (ASCVD) prevention following lung cancer screening in Missouri: A retrospective cohort study.

Eyerusalem Zewde, Isaac Che, Sri Gopalsamy Ramaswamy et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22537

e22537 Background: Individuals undergoing lung cancer screening (LCS) represent a population at elevated risk for Atherosc...

Clinical outcomes from a multi-institution precision oncology tumor board: The PROMOTE study update.

Jennifer Le Uyen Vu, Juhi Gor, Aseem Aseem et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23355

e23355 Background: The role of next generation sequencing to identify unique genetic makeup of a tumor has become monument...

Real-world pharmacovigilance analysis for antibody drug conjugates (ADCs) in treatment of solid tumor malignancies.

Sanad Alhushki, Mohammad Khaled Hashki, Ellen McNeeley et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20503

e20503 Background: Despite their efficacy in targeted cancer therapy, antibody-drug conjugates (ADCs) come with unique tox...

Association of immunoglobulin replacement with infection and mortality outcomes in multiple myeloma patients receiving bispecific antibodies: A TriNetX analysis.

Ahmad Al-Riyalat, Nadeen Majed Khraisat, Hassan Alkhatatneh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19526

e19526 Background: Bispecific antibodies have transformed the treatment landscape for relapsed or refractory multiple myel...

Clinical outcomes of immune checkpoint inhibitors in combination with tyrosine kinase inhibitors in metastatic MSS/pMMR colorectal cancer: A systematic review and meta-analysis.

Priyanshi Maurya, Mangesh Kritya, Vasu Bansal et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15593

e15593 Background: Immune checkpoint inhibitors (ICIs) have limited efficacy in microsatellite-stable or mismatch repair-p...

WhatsApp-based behavioral intervention and adherence to adjuvant endocrine therapy in early breast cancer: Real-world data from Brazil.

Larissa Costa, Loureno Cezana Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13706

e13706 Background: Adjuvant endocrine therapy significantly reduces recurrence and mortality in patients with early-stage...

Association between gabapentinoid exposure and chemotherapy-associated peripheral neuropathy among adults starting new neurotoxic chemotherapy in a multi-hospital health system.

Candrika Dini Khairani, Mahima Shenoi, Purva Shah et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24202

e24202 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dose-limiting toxicity of taxane, pla...

Effect of type and location of <i>BRCA2</i> deleterious variant on prognosis and survival in metastatic prostate cancer: A longitudinal, international, cohort study from hormone-sensitive to castration-resistant settings.

Lorena Incorvaia, Sergio Bracarda, Tarek Taha et al. Jun 01, 2026 pp. 10503-10503 10.1200/jco.2026.44.16_suppl.10503

10503 Background: Emerging evidence suggests that BRCA -altered prostate cancer (P...

Neurocognitive outcomes after proton versus photon radiotherapy in pediatric CNS tumors: Systematic review and meta-analysis.

Saloni Haldule, Harendra Kumar, Ashish Sharma et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22007

e22007 Background: Long-term neurocognitive impairment is a major source of disability in survivors of pediatric CNS tumor...

A phase Ib study of osimertinib and tegavivint as first-line therapy in patients with metastatic <i>EGFR</i> -mutated non–small cell lung cancer (NSCLC).

Regan Michelle Memmott, Jinesh S. Gheeya, Lai Wei et al. Jun 01, 2026 pp. 8648-8648 10.1200/jco.2026.44.16_suppl.8648

8648 Background: EGFR TKIs improve clinical outcomes for patients with EGFR-mutated NSCLC. However, they are not curative...

DISCO update: Diagnostic performance of <sup>64</sup> Cu-SARTATE compared to <sup>68</sup> Ga-DOTATATE in patients with known or suspected neuroendocrine tumors.

Eva Lengyelova, Grace Kong, Nimit Singhal et al. Jun 01, 2026 pp. 4174-4174 10.1200/jco.2026.44.16_suppl.4174

4174 Background: Diagnostic imaging is critical in the management of neuroendocrine tumors (NETs). 64...

Burden of mortality due to brain metastases secondary to lung cancer in the United States: A population-based study.

Dhivya Bharathi Govindaraj, Mohammed Shahzebuddin Baag, Vishan Das et al. Jun 01, 2026 pp. 2021-2021 10.1200/jco.2026.44.16_suppl.2021

2021 Background: Brain metastasis is a common and severe complication in lung cancer, contributing significantly to morbid...

A phase 1b/2 study of JK06, a 5T4-targeted antibody-drug conjugate (ADC), in patients with unresectable locally advanced or metastatic cancer.

Omar Saavedra, Fabricio Racca, Valentina Boni et al. Jun 01, 2026 pp. 3038-3038 10.1200/jco.2026.44.16_suppl.3038

3038 Background: 5T4, a Type I transmembrane glycoprotein, is over expressed in a broad spectrum of solid tumors. It modul...

Pan-cancer long mononucleotide repeat microsatellite instability testing for detection and immunotherapy selection.

Ruchi Shah, Katherine Anne Johnson, Elizabeth L. Field et al. Jun 01, 2026 pp. 2648-2648 10.1200/jco.2026.44.16_suppl.2648

2648 Background: Microsatellite instability (MSI) and mismatch repair deficiency (dMMR) are crucial biomarkers to inform p...

Telehealth and the patient experience in rural America.

Taylor Neilson, Rebecca A. Snyder, Fumiko Chino Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13708

e13708 Background: Rural populations face systemic barriers to healthcare, including specialty scarcity, travel burden, an...

Health-related quality of life with low-dose pembrolizumab plus chemotherapy in early triple-negative breast cancer: Findings from the PLANeT trial.

Adhip Arora, Hemavathi Baskarane, Ghazal Tansir et al. Jun 01, 2026 pp. 607-607 10.1200/jco.2026.44.16_suppl.607

607 Background: The PLANeT trial randomized stage II–III TNBC patients to neoadjuvant chemotherapy with or without low-dos...

Consensus molecular subtypes, mutational features, and circulating tumor DNA dynamics in colorectal cancer: A real-world clinico-genomic analysis.

Imad Shureiqi, Avinash Ramu, Vasily N. Aushev et al. Jun 01, 2026 pp. 3652-3652 10.1200/jco.2026.44.16_suppl.3652

3652 Background: Consensus molecular subtypes (CMS) define biologically distinct colorectal cancer (CRC) groups with diffe...

Predictors of response and safety profile of axatilimab in chronic GVHD: Pooled analysis of 384 patients.

Tehreem Asghar, Madho Mal, Syed Muhammad Ali Akbar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18564

e18564 Background: Chronic graft-versus-host disease (cGVHD) remains a significant complication following allogeneic hemat...

GGPP as a driver of esophageal squamous cell carcinoma progression via protein prenylation: Therapeutic potential of zoledronic acid repurposing.

Mengfei Zhao, Ruihua Kang, XiaoYang Wang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16104

e16104 Background: Esophageal cancer is a prevalent malignant tumor of the digestive system, with its development closely...

A phase 1, first-in-human study of OP-3136, a novel oral selective KAT6A/B inhibitor, as monotherapy in advanced solid tumors and in combination with endocrine therapy in ER+, HER2− advanced breast cancer (ABC): Preliminary results.

Amita Patnaik, Manish R. Sharma, William Bennion McKean et al. Jun 01, 2026 pp. 3088-3088 10.1200/jco.2026.44.16_suppl.3088

3088 Background: Histone lysine acetyltransferases (KATs) control oncogenic transcription and are frequently dysregulated...

Intratumoral heterogeneity of <i>MTAP</i> loss by immunohistochemistry in non–small cell lung cancer: Implications for clinical outcomes.

Tsuyoshi Hirata, Hibiki Udagawa, Tetsuro Taki et al. Jun 01, 2026 pp. 8025-8025 10.1200/jco.2026.44.16_suppl.8025

8025 Background: MTAP-cooperative PRMT5 inhibitors are under development for MTAP-loss solid tumors including non-small ce...

Performance of a cfDNA methylation–based MCED test in patients with clinicoradiologic suspicion of cancer.

Elie Massaad, A. Gregory DiRienzo, Johanna B. Withers et al. Jun 01, 2026 pp. 10543-10543 10.1200/jco.2026.44.16_suppl.10543

10543 Background: Radiographic findings concerning for malignancy frequently prompt extensive diagnostic evaluations that...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page